Michael Gejl

In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Michael Gejl, Albert Gjedde, Lærke Egefjord et al. · Frontiers in Aging Neuroscience · 2016 · 453 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment

Michael Gejl, Birgitte Brock, Lærke Egefjord et al. · Scientific Reports · 2017 · 154 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Quantitative Rates of Brain Glucose Metabolism Distinguish Minimally Conscious from Vegetative State Patients

Johan Stender, Ron Kupers, Anders Rodell et al. · Journal of Cerebral Blood Flow & Metabolism · 2014 · 130 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Capillary dysfunction is associated with symptom severity and neurodegeneration in Alzheimer's disease

Rune B. Nielsen, Lærke Egefjord, Hugo Angleys et al. · Alzheimer s & Dementia · 2017 · 120 citations

Life Sciences, Neurology, Neuroscience +17

Regional cerebral effects of ketone body infusion with 3-hydroxybutyrate in humans: Reduced glucose uptake, unchanged oxygen consumption and increased blood flow by positron emission tomography. A randomized, controlled trial

Mads Svart, Lars Christian Gormsen, Jakob Hansen et al. · PLoS ONE · 2018 · 105 citations · Full text

Medicine, Neuroscience, Pharmacology +17